Von Willebrand Factor in Plasma of Patients with Advanced Stages of Larynx Cancer

Paczuski, Ryszard; Białkowska, Aneta; Kotschy, M; Burduk, Danuta; Betlejewski, S

doi:10.1016/s0049-3848(99)00041-9

Cited by 17 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients with GBM in our study had supraphysiological VWF:Ag levels and the higher was the VWF level the shorter was the survival rendering VWF:Ag levels a putative prognostic factor. Such a prognostic role for VWF has been shown in patients with other type of cancer, being high VWF levels associated with disease stage, 33, 34, 35, 36, 37, presence of metastases and/or lymph node status 33, 34, 36, 37, tumor size and residual disease after surgery 35. All in all, this study showed a significantly reduced survival in patients with GBMs and preoperative high levels of VWF:Ag in plasma irrespective of age.…”

Section: Discussionmentioning

confidence: 76%

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

et al. 2016

View full text Add to dashboard Cite

Circulating biomarker for malignant gliomas could improve both differential diagnosis and clinical management of brain tumor patients. Among all gliomas, glioblastoma (GBM) is considered the most hypervascularized tumor with activation of multiple proangiogenic signaling pathways that enhance tumor growth. To investigate whether preoperative antigen plasma level of von Willebrand Factor (VWF:Ag) might be possible marker for GBM onset, progression, and prognosis, we retrospectively examined 57 patients with histological diagnosis for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, enrolled as controls. Blood samples were collected from all the patients before tumor resection. Plasma von Willebrand Factor (VWF):Ag levels were determined by using a latex particle‐enhanced immunoturbidimetric assay. The median levels of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) (183 vs. 133 IU/dL, P = 0.01). The cumulative 1‐year survival was significantly shorter in patients with VWF:Ag levels >200 IU/dL than in those with levels <200 IU/dL and increased VWF levels were associated with a threefold higher risk of death in GBM patients. Our data suggest that VWF:Ag could be a circulating biomarker of disease malignancy, that could be considered, in association with other genetic and epigenetic factors, currently available in the GBM management. Future studies should investigate whether plasma VWF:Ag levels could also be used to monitor therapeutic effects and whether it may have a prognostic value.

show abstract

Section: Discussionmentioning

confidence: 76%

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In this context, it is interesting to note that numerous studies have shown that cancer patients have elevated levels of plasma VWF, in addition to other coagulation factors, which all may contribute to thrombotic risk. These include laryngeal (Paczuski et al ., 1999), renal (Oleksowicz et al ., 1999), colorectal (van duijnhoven et al ., 1993), cervical (Gadducci et al ., 1993), prostate (Ablin et al ., 1988), and head and neck cancers (Sweeney et al ., 1990). Moreover, Oleksowicz et al .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, patients with malignant breast cancer have increased VWF content in the cytosol of the malignant tissue (Pratt et al ., 1989). Importantly, it has been demonstrated that the staging and tumour size correlate with disease progression whereby patients with higher plasma VWF have more advanced disease (Paczuski et al ., 1999; Gadducci et al ., 1993; Pratt et al ., 1989). Experimentally, co‐culture of human HRT‐18 colon cancer cells with human umbilical vein endothelial cells leads to an increase in VWF release from the endothelial cells and this may lead to enhanced platelet adhesion (Morganti et al ., 1996).…”

Section: Discussionmentioning

confidence: 99%

Role of von Willebrand factor in tumour cell‐induced platelet aggregation: differential regulation by NO and prostacyclin

Jurasz

Stewart²,

Radomski

et al. 2001

British J Pharmacology

View full text Add to dashboard Cite

1 We have studied the e ects of a novel agonist, solid-phase von Willebrand Factor (sVWF), on tumour cell-induced platelet aggregation (TCIPA). 2 Washed platelet suspensions were obtained from human blood and the e ects of HT-1080 human ®brosarcoma cells and sVWF on platelets were studied using aggregometry, phase-contrast microscopy, and¯ow cytometry. 3 Incubation of platelets with sVWF (1.2 mg ml 71 ) and HT-1080 cells (5610 3 ml 71 ) resulted in a two-phased reaction characterized ®rst by the adhesion of platelets to sVWF, then by aggregation. 4 TCIPA in the presence of sVWF was inhibited by S-nitroso-glutathione (GSNO, 100 mM) and prostacyclin (PGI 2 , 30 nM). 5 Platelet activation in the presence of tumour cells and sVWF resulted in the decreased surface expression of platelet glycoprotein (GP)Ib and up-regulation of GPIIb/IIIa receptors. 6 Pre-incubation of platelets with PGI 2 (30 nM) resulted in inhibition of sVWF-tumour cellstimulated platelet surface expression of GPIIb/IIIa as measured by¯ow cytometry using antibodies directed against both non-activated and activated receptor. In contrast, GSNO (100 mM) did not a ect sVWF-tumour cell-stimulated platelet surface expression of GPIIb/IIIa. 7 Flow cytometry performed with PAC-1 antibodies that bind only to the activated GPIIb/IIIa revealed that GSNO (100 mM) caused inhibition of activation of GPIIb/IIIa. 8 The inhibitors exerted no signi®cant e ects on TCIPA-mediated changes in GPIb. 9 Thus, sVWF potentiates the platelet-aggregatory activity of HT-1080 cells and these e ects appear to be mediated via up-regulation of platelet GPIIb/IIIa. 10 Prostacyclin and NO inhibit TCIPA-sVWF-mediated platelet aggregation. The mechanisms of inhibition of this aggregation by PGI 2 di er from those of NO.

show abstract

“…Increased levels of soluble P-selectin (sP-selectin), an adhesion molecule and a component of the membrane of the platelet alpha granule, have been detected in hematological and breast cancers [6], and have been shown to correlate with clinical stage in melanoma [7]. von Willebrand factor (vWf), an adhesive ligand with platelets, has also been shown to be elevated in advanced and disseminated malignancies, such as prostate cancer [8], cervical and ovarian cancer [9], and larynx cancer [10], and it is involved in the metastatic process through the activation of thrombin [11,12].…”

Section: Introductionmentioning

confidence: 99%

Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor

et al. 2002

View full text Add to dashboard Cite

Background. Angiogenesis and hemostatic activation are important factors in tumor progression and metastasis. Because surgical intervention induces tissue hypoxia and hemostatic activation, we analyzed the effect of gastric surgery on the plasma concentrations of vascular endothelial growth factor (VEGF), soluble P-selectin (sP-selectin), and von Willebrand factor (vWf). Methods. Plasma VEGF, sP-selectin, and vWf concentrations were measured in 14 patients with gastric cancer before operation and on postoperative day 1 (POD 1). Correlations between disease stage and the effect of surgical intervention were analyzed. Results. The plasma concentrations of these three factors did not correlate with the disease stage. Plasma levels of sPselectin did not change after operation (before surgery, 87.6 ؎ 34.1 ng /ml; on POD 1, 101.1 ؎ 48.1 ng/ml; P ‫؍‬ 0.123). Plasma VEGF and vWf concentrations were significantly elevated on POD 1 (VEGF, 33.3 ؎ 20.5 pg /ml before surgery and 61.9 ؎ 35.6 pg /ml on POD 1; P ‫؍‬ 0.0013; vWf, 164 ؎ 31.1% before surgery and 211.1 ؎ 66.1% on POD 1; P ‫؍‬ 0.027). Conclusion. Because VEGF and vWf are involved in angiogenesis, tumor-platelet adhesion, and tumor-endothelial cell adhesion, surgical intervention could influence tumor growth and metastasis.

show abstract

Von Willebrand Factor in Plasma of Patients with Advanced Stages of Larynx Cancer

Cited by 17 publications

References 16 publications

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma

Role of von Willebrand factor in tumour cell‐induced platelet aggregation: differential regulation by NO and prostacyclin

Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor

Contact Info

Product

Resources

About